company background image
PSG logo

PharmaSGP Holding DB:PSG Stock Report

Last Price

€24.40

Market Cap

€302.2m

7D

-0.8%

1Y

24.2%

Updated

14 Nov, 2024

Data

Company Financials +

PSG Stock Overview

Manufactures and sells over-the-counter drugs and other healthcare products in Germany. More details

PSG fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance4/6
Financial Health5/6
Dividends4/6

PharmaSGP Holding SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PharmaSGP Holding
Historical stock prices
Current Share Price€24.40
52 Week High€27.00
52 Week Low€18.00
Beta-0.10
11 Month Change3.39%
3 Month Change18.45%
1 Year Change24.17%
33 Year Change-1.21%
5 Year Changen/a
Change since IPO-31.46%

Recent News & Updates

Recent updates

Shareholder Returns

PSGDE PharmaceuticalsDE Market
7D-0.8%-6.3%-0.6%
1Y24.2%-21.6%9.6%

Return vs Industry: PSG exceeded the German Pharmaceuticals industry which returned -20.4% over the past year.

Return vs Market: PSG exceeded the German Market which returned 7.8% over the past year.

Price Volatility

Is PSG's price volatile compared to industry and market?
PSG volatility
PSG Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement8.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.0%
10% least volatile stocks in DE Market2.4%

Stable Share Price: PSG has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: PSG's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201289Natalie Weigandpharmasgp.com

PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.

PharmaSGP Holding SE Fundamentals Summary

How do PharmaSGP Holding's earnings and revenue compare to its market cap?
PSG fundamental statistics
Market cap€302.15m
Earnings (TTM)€18.21m
Revenue (TTM)€109.76m

16.6x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PSG income statement (TTM)
Revenue€109.76m
Cost of Revenue€9.98m
Gross Profit€99.78m
Other Expenses€81.57m
Earnings€18.21m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 28, 2024

Earnings per share (EPS)1.52
Gross Margin90.91%
Net Profit Margin16.59%
Debt/Equity Ratio212.5%

How did PSG perform over the long term?

See historical performance and comparison

Dividends

5.4%

Current Dividend Yield

90%

Payout Ratio